The tweet was deleted by the author.
But we saved everything 🙂.
Michael Taylor, co-founder / portfolio manager at Agora Trading, outlines his positive interpretation of recent FDA meeting minutes regarding BNTC.
He highlights that the FDA has requested a one-year natural history control group, a Phase 3 single arm study, and a six-month interim endpoint. Taylor expects the study to enroll very quickly, with a readout anticipated in the second half of 2027 at six months.
View post on X Loading...
Taylor recently highlighted AQRT's planned Phase 2 Vitiligo study, which aims to double the company’s total addressable market to $1 billion in the fourth quarter of 2026 (link). He also covered a $2 billion preferred convertible agreement between Summit Therapeutics and AstraZeneca to advance lung cancer therapies (link). These previous updates reflect Taylor's continued focus on clinical study progress and major biopharma deals.